Finland· FI-REL-REL40962
Ryzodeg FlexTouch
A insulin degludec und insulin aspart product containing insulin degludec + insulin aspart, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec und insulin aspart is registered in 9 of 19 countries.
Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Insulin degludec und insulin aspart · ATC A10AD06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Insulin degludec + Insulin aspart
- Manufacturer
- Novo Nordisk A/S
- Country
- Finland (FI)
- ATC code
- A10AD06
- ATC class
- Insulin degludec und Insulin aspart
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec und insulin aspart in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYZODEGNovo Nordisk A/S, Bagsvaerd
- SwedenRyzodeg FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SwitzerlandRyzodeg FlexTouch , InjektionslösungNovo Nordisk Pharma AG
- NetherlandsRyzodeg 100 eenheden/ml oplossing voor injectie in patroonNovo Nordisk A.S.
- IcelandRyzodegNovo Nordisk A/S*
- PolandRyzodegNovo Nordisk A/S
- IrelandRyzodeg 100 units/mL solution for injectionNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Ryzodeg Flexpen, Ryzodeg Flextouch
- Norway · Ryzodeg Flexpen, Ryzodeg Flextouch
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/294216c7-2aae-427c-abac-38b8cda24515 GET /v1/drugs/294216c7-2aae-427c-abac-38b8cda24515?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "40",
"form": "injektioneste, liuos, esitäytetty kynä",
"route": "Ihon alle",
"ddd_unit": "U",
"strength": "100 U/ml",
"atc_label": "degludekinsuliini ja aspartinsuliini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/12/806/001-005",
"fimea_rel_id": "REL40962",
"authorised_at": "2013-01-21"
}See everything about insulin degludec und insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.